Liquid biopsy test to screen for lymphoma in people with HIV
Official title: Validation of a Liquid Biopsy Assay for Early Detection of Lymphoma in People with HIV
Funded at Yale University · NIH-11440158 · Data updated 2026-11-12
A new blood test called High Density Methyl-Seq is being checked to see if it can detect lymphoma early in people living with HIV.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $279,018 |
| NIH project number | 1UH2CA308227-01A1 |
| Project ID | NIH-11440158 on NIH RePORTER |
Who could benefit from this research
✓Could help
People living with HIV who are at elevated risk for non-Hodgkin’s lymphoma and who have plasma samples available for testing.
✕Less likely to help
Patients without NHL or without access to the testing workflow may not benefit.
What this research studies
This project will validate a liquid biopsy method using circulating DNA to find methylation signals linked to non-Hodgkin’s lymphoma in people with HIV. Researchers will analyze pre-diagnosis plasma samples from a large HIV-focused cohort to determine how accurately the test identifies NHL before it becomes advanced. The effort combines analytical and clinical validation to ensure the test is reliable enough for clinical use. If successful, this could lead to earlier treatment decisions and better outcomes for patients with HIV who are at higher risk of NHL.
Why it matters
Potential benefit: If successful, the test could enable earlier detection of NHL in people with HIV, potentially improving survival and quality of life.
How similar studies have gone: Preliminary studies have shown NHL-specific methylation signals in plasma up to a year before diagnosis, supporting further validation.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Patel, Abhijit — Yale University
- Study coordinator: Patel, Abhijit
Related research
Other NIH-funded projects on the same topics.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Preventing follicular lymphoma progression with precision therapy
This grant tests a targeted approach to stop follicular lymphoma from getting worse or turning into a more aggressive cancer.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Towards a blood-based test using nanophotonic exosomes to screen and diagnose liver cancer
A new blood test using tiny particles shed by liver cancer cells aims to screen for hepatocellular carcinoma earlier and more accurately.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
-
Targeting the IL-1R Pathway to Boost Immunotherapy for Anaplastic Large Cell Lymphoma
Aims to make CD30 CAR therapies work better for people with ALCL by blocking a immune-evasion pathway.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.